Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 1

Status

Recruiting 3

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Neuroblastoma 5Ganglioneuroblastoma 3Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Bone Neoplasms 1

Interventions

dinutuximab 3Magnetic Resonance Spectroscopy 3Doxorubicin 3Cyclophosphamide 3Carboplatin 3Biopsy 3Vincristine 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Irinotecan 2Etoposide 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2sargramostim 1lorlatinib 1etoposide phosphate 1Watchful Waiting 1Transurethral Resection of Bladder 1Razoxane 1Radiotherapy 1Observation 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Ganglioneuroblastoma × dinutuximab × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07375563 2026-01-29

NB-NK-2026

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 3 Recruiting
5 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡